Ruti Aga's Six-Year Ban: A Forged Prescription for a Knee Injection — and the Mistake Nobody Corrected

Last March, at 2 a.m. UK time, I opened a stream of a half marathon in China. There were no splits on screen — only a top-ten list and times to two decimal places. Ruti Aga of Ethiopia won it. Six months later that same race reappeared inside an Athletics Integrity Unit (AIU) statement, and the win was no longer a result. It was a sample collection point. The mark from that race has still not appeared in any report.

The smallest gap is usually where the story waits. In this case the smallest gap is not a hundredth of a second — it is the gap between two years and four years, because Aga received a six-year ban and four of those years belong not to a drug but to a piece of paper.

The name that stayed outside the headline

Ruti Aga, 32, Ethiopian marathoner. Winner of the 2026 Tokyo Marathon, three second-place finishes at World Marathon Majors, a 2:18–2:20 athlete — the tier where a place on the Ethiopian team is never automatic, because the world-record class sits above her, the sub-2:16 cohort sits around her, and a 2:18 runner is not automatically selectable. That context matters, because it determines how much of this case is about the sport and how much is about governance.

The AIU statement came on a Thursday. According to it, a sample taken after she won a half marathon in China in March returned methylprednisolone. Her explanation was that the substance had been administered to treat a knee injury, and a prescription was produced in support. The investigation found the prescription forged. The clinic that supposedly issued it did not exist; the person who issued it was a family member with no medical registration; and that person attempted to save the document by claiming it came from an old prescription pad from a former workplace — a workplace that explicitly disowned any connection to the pad.

The sanction arithmetic is plain: two years for presence of the substance, four years for providing a misleading document during the investigation. Six years in total, running from 10 September — the same date her provisional suspension began. I learned to read a scoreboard like a passport stamp: dates do not tell you a story, they tell you where you may and may not stand. A six-year ban at 32 means a return at roughly 38, and in the depth of Ethiopian women's marathoning there is no place for a 38-year-old returnee carrying a doping record.

The drug was not the one that got printed

Methylprednisolone is not an anabolic steroid. It is a glucocorticoid, WADA Prohibited List class S9, and that class is prohibited in-competition only — by injection, oral or rectal route. Anabolic steroids sit in class S1, and those are prohibited at all times. The distinction is not technical. It is decisive.

Because in S9 the question is never the drug. It is the route and the timing. A therapeutic injection into the knee, administered out of competition, is entirely legal. It becomes a violation at the moment residues are present in a sample taken in competition. And a road race's in-competition window opens at 23:59 the day before the race. An injection given days earlier will be caught, whether or not it was given as treatment. That is the mechanical reason this case exists.

And that is exactly where Aga had a real defence. If the knee treatment genuinely happened and genuine medical records existed, the argument was available that this was therapeutic use, that the error lay in route and timing, and that the matter therefore belonged at the no-fault or no-significant-fault end — a reprimand or a substantially reduced period, and no tampering charge at all. In the best case, a TUE and a correct washout window would have meant no case whatsoever.

Instead, what exists is a chain of three independent verification failures: a clinic with no existence, an issuer with no registration, and a prescription pad disowned by the workplace it was attributed to. None of those three checks happened in a laboratory. All of them happened in paperwork.

This case was decided by document verification, not by chemistry. That is the sentence that separates this story from the rest of doping reporting, and it is the sentence most coverage lost.

What two and four mean

The sanction architecture is standard, not exceptional. Two years is the standard outcome for presence of a Specified Substance without proven intent. Four years is the Code's standard tampering sanction. Added together they make six, and the sum carries its own information: the panel rejected the no-significant-fault mitigation that would have reduced the presence charge.

There is a near-paradox worth marking: forged documents are themselves circumstantial evidence of concealment intent — yet they did not escalate the presence sanction. They generated a separate sanction instead. The panel weighed two offences on two scales rather than stacking them.

And one thing the statement does not say but standard practice makes clear: the March race result and its prize money are almost certainly annulled, because disqualification of the competition at which the sample was collected is automatic. By contrast, the 2026 Tokyo title does not fall automatically — absent a finding of earlier use, results before that date stand. The reporting gave no scope for the disqualification at all.

That silence is part of the story rather than a gap in it. When a case prints the start date of a ban but not the boundary of the annulled results, the reader assumes everything is gone. It is not.

The knee, the agent and the medical system

The root cause is not the drug. It is the knee. Chronic knee pathology is a known load-bearing failure mode in high-volume marathoners, and the knee injury in this case came from Aga's own account. Intra-articular or peri-articular methylprednisolone is standard sports-medicine practice in distance runners. That is the most uncomfortable fact here: the medically plausible explanation is precisely the one that proved legally fatal, because a genuine treatment would have been defended with genuine records.

And the systemic signal starts here. No credentialed team physician is visible around Aga. No TUE infrastructure is visible — no application, no exemption, no route-specific washout plan. What is visible is an injured athlete, a race calendar dependent on appearance fees, and an informal medical network in which a family member becomes a doctor.

China's label-race circuit has been a lucrative, low-risk income tier for East African marathoners between Majors. That same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding inside the same races — and in that collision the injured athlete is always on the weaker side, because skipping a race means losing money directly.

The competitive landscape is essentially untouched. Ethiopia's women's marathon depth is such that the removal of one 32-year-old changes national-team capacity by no measurable margin. What moves here is not the medal table. It is the administration.

One word, dropped, that changes the whole story

Most reports called methylprednisolone a prohibited steroid and stated that WADA classes it as performance enhancing. Both are incomplete. A glucocorticoid reduces inflammation, suppresses pain, and permits an injured runner to keep training or to start. It has no proven endurance-enhancing capacity.

There are two consequences of that error. First, the reader concludes that some endurance advantage was purchased — it was not; what was purchased was pain suppression, which is permission to stand on a start line, not speed. Second, a six-year ban gets read as a drug sentence when five-sixths of it belongs to a document.

This is where I distrust my own habit. The counter-intuitive angle is so attractive that I want to apply it to every case. This time the scales are clean: the sanction arithmetic dissents from the headline, so the angle holds. Two years drug, four years paper. If the numbers had agreed, I should not have written this section at all.

It must also be said plainly that the tampering is Aga's own act. An agent may have handed her the forged prescription, but she filed it. A real prescription would have survived. Turning this into a victim narrative would be as large an error as calling it a steroid. The fair question is whether six years is disproportionate for a substance with no proven endurance benefit — and the honest answer is that four of those six years were never about the substance.

Who checks the prescription next time

The AIU's leverage is shifting from the laboratory to the notary, and Aga's case is not an outlier — it belongs to a recognisable family of East African road-racing cases in which the first violation is chemical and the second, heavier one is explanatory. Until injured runners have access to a credentialed team doctor and a functioning TUE pathway, the person writing the prescription will keep being a relative. And as scrutiny intensifies over China's label circuit, more of these cases will surface.

The next time an Ethiopian woman stands on a start line with a sore knee, the question will not be what she is taking. The question will be who read her prescription, and whose job it was to read it.